Browsing by Author "Grove, Erik Lerkevang"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to actionPublication . Luedde, Mark; Agewall, Stefan; Ambrosio, Giuseppe; Bayes‐Genis, Antoni; Borghi, Claudio; Cerbai, Elisabetta; Dan, Gheorghe A.; Drexel, Heinz; Ferdinandy, Péter; Grove, Erik Lerkevang; Kaski, Juan Carlos; Klingenberg, Roland; Morais, João; Parker, William; Petrie, Mark; Rocca, Bianca; Semb, Anne Grete; Senni, Michele; Sohns, Christian; Sulzgruber, Patrick; Tamargo, Juan; Metra, Marco; Böhm, Michael; Dobrev, Dobromir; Sossalla, SamuelHeart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non-adherence and side effects. While rhythm control strategies in AF have gained attention for their prognostic benefits in HF, the pharmacological treatment of HF in patients with AF, including the benefit of rhythm versus rate control, remains underexplored. The relationship between HF and AF lacks sufficient evidence and targeted research to assess the optimal treatment strategies. This narrative review critically examines current HF pharmacotherapy in the context of AF, focusing on the four cornerstone treatments and modifiers of prognosis for HF with reduced ejection fraction: beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/sacubitril-valsartan, aldosterone antagonists, and sodium–glucose co-transporter 2 inhibitors. Although these therapies are well-established in HF patients, their efficacy in patients with concomitant AF requires further prospective investigation. The unique challenges posed by AF, including arrhythmia-induced remodelling and cardiomyopathy, necessitate a more individually tailored treatment. We also highlight critical knowledge gaps and the need for dedicated clinical trials specifically assessing HF therapies in AF subgroups, such as paroxysmal, long-standing persistent and permanent AF, and the benefit of heart rate and rhythm control strategies. The future of precision medicine in HF-AF management lies in bridging these evidence gaps through targeted research and interdisciplinary collaboration.
- New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024Publication . Tamargo, Juan; Agewall, Stefan; Ambrosio, Giuseppe; Borghi, Claudio; Cerbai, Elisabetta; Dan, Gheorghe A; Drexel, Heinz; Ferdinandy, Péter; Grove, Erik Lerkevang; Klingenberg, Roland; Morais, João; Parker, William; Rocca, Bianca; Sulzgruber, Patrick; Semb, Anne Grete; Sossalla, Samuel; Kaski, Juan Carlos; Dobrev, DobromirDespite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVDs) remain limited, thus reflecting the need for more effective and safer pharmacological strategies. In this review, we summarize the most relevant studies in cardiovascular pharmacotherapy in 2024, including the approval of first-in-class drugs for the treatment of resistant hypertension and pulmonary arterial hypertension, label expansions for bempedoic acid and semaglutide, and the results of major randomized clinical trials (RCTs) that have met the pre-specified primary endpoints, thereby filling some gaps in knowledge and opening new perspectives in the management of CVD, and those RCTs whose results did not confirm the proposed research hypotheses. We also include a section on drug safety, where we describe the newest data on adverse reactions and drug–drug interactions that may complicate treatment and/or reduce drug adherence with the consequent decrease in drug effectiveness. Finally, we present the most important ongoing phase 2 and phase 3 clinical trials assessing the efficacy and safety of cardiovascular drugs for the prevention and treatment of CVD.